The stock of Sutro Biopharma Inc (STRO) has gone down by -5.13% for the week, with a -15.56% drop in the past month and a 28.34% rise in the past quarter. The volatility ratio for the week is 10.04%, and the volatility levels for the past 30 days are 9.20% for STRO. The simple moving average for the last 20 days is -4.90% for STRO stock, with a simple moving average of -60.48% for the last 200 days.
Is It Worth Investing in Sutro Biopharma Inc (NASDAQ: STRO) Right Now?
The 36-month beta value for STRO is at 1.66. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for STRO is 78.04M, and currently, shorts hold a 9.69% of that float. The average trading volume for STRO on July 03, 2025 was 1.64M shares.
STRO) stock’s latest price update
Sutro Biopharma Inc (NASDAQ: STRO) has seen a rise in its stock price by 12.35% in relation to its previous close of $0.68. However, the company has experienced a -5.13% decline in its stock price over the last five trading sessions. zacks.com reported 2025-05-08 that Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
Analysts’ Opinion of STRO
Many brokerage firms have already submitted their reports for STRO stocks, with Piper Sandler repeating the rating for STRO by listing it as a “Overweight.” The predicted price for STRO in the upcoming period, according to Piper Sandler is $2 based on the research report published on June 16, 2025 of the current year 2025.
Wedbush gave a rating of “Neutral” to STRO, setting the target price at $2 in the report published on March 14th of the current year.
STRO Trading at -12.85% from the 50-Day Moving Average
After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.22% of loss for the given period.
Stock Fundamentals for STRO
Current profitability levels for the company are sitting at:
- -3.77 for the present operating margin
- 0.04 for the gross margin
The net margin for Sutro Biopharma Inc stands at -3.69. The total capital return value is set at -1.33. Equity return is now at value -679.15, with -67.66 for asset returns.
Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated -4.85 points at debt to capital in total, while cash flow to debt ratio is standing at -9.1. The debt to equity ratio resting at -0.83. The interest coverage ratio of the stock is -6.9.
Currently, EBITDA for the company is -180.45 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of -0.31. The receivables turnover for the company is 4.9for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In conclusion, Sutro Biopharma Inc (STRO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.